أفضل تشخيص شامل لأمراض القولون والمستقيم أطباء الجهاز الهضمي - توب -62 أطباء

بيتشاي كيتيبانياوراكول، دكتور في الطب
بيتشاي كيتيبانياوراكول، دكتور في الطب

الطب الباطني / طبيب الجهاز الهضمي والكبد

التخرج (دكتوراه في الطب)

بكالوريوس الطب، كلية الطب، جامعة شيانغ ماي

الشهادات

دبلوم في الطب الباطني، كلية الطب، مستشفى شولالونغكورن التذكاري، جمعية الصليب الأحمر التايلاندي

دبلوم الطب الباطني في أمراض الجهاز الهضمي والكبد، كلية الطب، مستشفى راماثيبودي، جامعة ماهيدول

المناصب الحالية

الطب الباطني / طبيب الجهاز الهضمي والكبد في مستشفى انترات

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

الدكتور سيجبرت روسول هو طبيب جهاز هضمي ذو خبرة عالية ولديه أكثر من 34 عامًا من الخبرة في هذا المجال. وهو عضو في العديد من الجمعيات الطبية ودرس الطب البشري والإدارة الصحية والتصوير فوق الصوتي التداخلي. وقد نشر العديد من المقالات ولديه خبرة استثنائية في العلاج بالمنظار وعلاج الحاجز الداخلي ومرض التهاب الأمعاء.

Gastroenterology

Pendik Medipol University Hospital

Education

1999 Karadeniz Technical University, Gastroenterology

1997Atatürk University, Internal Diseases Professorship

1992 Atatürk University, Internal Diseases Associated Professorship 

1985 Atatürk University, Internal Diseases Specialist 

1981 Atatürk University Faculty of Medicine

Publications

1- Nihat Okçu Gülçin Polat,Arif Yılmaz,Mehmet Koruk,The demographıc features of gastrıc cancers ın erzurum(Eurasian J Med 2000; 32: 63-65)

2- Üst Gastrointestinal Kanamalı Olguların Bir Değerlendirilmesi. Klinik Bilimler-Doktor.2000, - E.akarsu,N.Okçu, ve Ark.Kuzeydoğu Anadolu’da 6:4:435-438

3-N.Okçu, A.yılmaz. İ.kiki,M.D.onuk, C.gündoğdu, H.uzunismail. Tanısal Üst Gastrointestinal endoskopi Sonuçlarımız. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):486

4-N. Okçu, M.gündoğdu, M.D. onuk, İ.kiki, l.cerrahoğlu, k.yılmaz, i. çapoğlu. Nonsteroid Anti İnflamatuar İlaç (NSAİİ) Kullanan Hastalarda oluşan Gastroduodenal Lezyonların Önlenmesinde Misoprostolün Yeri. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):453-455.

5-N.Okçu, A. öz, m.d. onuk, e.akarsu, b. tekin, h.z. tonbul, h.kaya. Kronik Aktif Hepatit İle Dekopanse Karaciğer Parankim Yetmezliğinde Plazma Fibronektin Düzeyleri ve Karaciğerin Fonksiyon Durumu İle İlişkisi. Türk J. Gastroenterol 1995;27(4): 422-426.

6-N.Okçu, tahir buran,m.d. onuk,a. yılmaz, e.akarsu, g. akçay. Erzurum ve Çevresinde Duodenum Ülserli Hastalarda Helicobacter Pylori Prevelansı. Türk J. Gastroenterol 1995;27(4): 447-450.

7-N.Okçu, b.s. uyanık, e. akarsu, e. bakan, z. tonbul. Mide ve Kolorektal Kanserlerinde Karbonhidrat Antijenleri (CA-19-9, CA-125), Karsinoembriyonik Antijen (CEA) ve Alkalen Fosfatazın Önemi. Türk J. Gastroenterol 1995;6:467-471.

8-N. Okçu, m.d. onuk, e. akarsu, h. doğan, c. gündoğdu. Bölgemizdeki Hepatoselüler Karsinomlu Hastalarda Major Risk Faktörleri. Gastroenteroloji 1994;5(2):154-157

9-N.Okçu, m.d. onuk, e. akarsu, h. doğan, c.gündoğdu, tahir buran. Erzurum Bölgesinde Gastrik Karsinom Sıklığı, Endoskopik ce Histolojik Özellikler. Gastroenteroloji 1994;5(2):263-267.

10-N. Okçu, m.d. onuk, tahir buran, e. akarsu, m.a. çiftçioğlu. Erzurum İli Çevresinde Nonspesifik Gastritli Olgularda Helicobacter Pylori Sıklığı. Gastroenteroloji 1994;5(2):211-213.

11-N.Okçu, m.d. onuk, ö. ünal, e. akarsu, l. incesu, k. akgöz. Karın İçi Kitle Lezyonlarında Ultrason Rehberliğinde Yapılan İnce İğne Aspirasyon Biyopsisinin Tanı Değeri. Gastroenteroloji 1993;4(1):166-68.

12-N.O.kçu, m.d. onuk, m. polat, a. yılmaz, m. gündoğdu, m. paç. Budd-Chiari Sendromu (2 Olgu). Türk J Gastroenterhepatol 1993; 4(1):77-80.

13-N.Okçu, h. koçak, m.d. onuk, m. gündoğdu, e. bakan, a. yılmaz, a. başoğlu, a. ateş, f.a. paç. The Effect of Atrial Pressure Changes and Cardiac Nerves on Plasma Atrial Natriüretic Peptide (ANP) Levels. Vascular Surgery 1993; 27(2): 128-132

15-N.Okçu, m.d. onuk, a.yılmaz, m. gündoğdu, t. buran. Omeprozol ve Ranitidinin Peptik Ülser İyileşmesine Etkileri. Doğa-Tr.J. of Medical Sciences 1992;16:657-658.

16-N. Okçu, m.r. yiğitoğlu, b. adam, e. bakan. Konjestif Kalp Yetersizliği Olan Hastalarda Digıxin’in Plazma Atrial Natriüretik Peptik Düzeyine Etkisi. S.Ü. Tıp Fak. Dergisi 1991;7(2):243-247..

17-N.Okçu, a. yılmaz. Üst Gastrointestinal Sistem Kanamalarında Histamin H2 -Reseptör Antagonistlerinin Etkisi. Endoskopi Dergisi 1991;2(4):17-23.

18-N.Okçu, E. bakan, b. adam, a. yılmaz, m.r. yiğitoğlu. Kronik Hepatit ve Karaciğer Sirozlu Hastalarda Seks Hormanları ve Seks Hormon Bağlayıcı Globülin Seviyeleri (Editöre Mektup). Doğa-Tr. J. Of Medical Sciences 1991;15:1-2.

19-N.Okcu Ömer Yılmaz.Helıcobacter pylorı and related gastroıntestınal system dıseases Turkiye Klinikleri JMed Sci. 2013;33(3):806-13

20-Nihat Okçu , Ömer yılmaz, hakan dursun, gülçin polat. Dispeptik semptomlarla beslenme alışkanlıkları, endoskopik ve histolojik bulgular arasındaki ilişki (Eurasian J Med 2006; 38: 13-17)

21-Mehmet Bilici,1Nihat Okcu,1Kerim Cayır,1Ibrahim Pirim,2Salim B. Tekin,1andCemal Gundogdu3 - Distribuion of HLA Tissue Groups in Patients with Gastric Cancer Eurasian J Med. 2010 Apr; 42(1): 9.11.

22-Nihat Okcu,Abdulhalim Bak,Mehmet Sari,Mehmet Arslan,Sait Kapicioglu :The fibroblast proliferation,relationship of hepatocyte growth factor (HGF) and interferon-A2A Gastroenterology April 2000Volume 118,Issue 4, Part 2, PageA1404

23-Kubra Kaynar,Sait Kapicioglu,Mehmet Sarı,Nihat Okcu,Abdulhalim Baki. The effect of fish oil on stress ulcer prophylaxis GastroenterologyVolume 118, Issue 4, Part 2, PageA1255

دكتور. فلاديمير يوتكين طبيب مؤهل تأهيلا عاليا في مركز هداسا الطبي ولديه أكثر من 20 عاما من الخبرة في تشخيص وعلاج سرطانات المسالك البولية ومدير قسم أورام المسالك البولية. تخرج من الجامعة العبرية في القدس عام 1996 ويتحدث الإنجليزية والعبرية والروسية.

مرخص أخصائي علاج الأورام بالإشعاع مع 8 سنوات من التدريب الطبي ، بما في ذلك الدراسات الجامعية في كلية الطب بجامعة مرمرة (2004-2011) والتدريب المتخصص في علاج الأورام بالإشعاع في كلية الطب بجامعة مرمرة (2012-2016). التعليم السابق من مدرسة Sixteen Numbered Shirvan School (أذربيجان) الثانوية (1998-2004).

الدكتور راج هو طبيب أورام جراحي ذو خبرة عالية ولديه 19 عامًا من الخبرة وأكثر من 50000 عملية جراحية للسرطان. يشارك في العديد من التجارب السريرية وله العديد من المنشورات الدولية والوطنية لحسابه. وهو متخصص في جراحة أورام الثدي والصدر ويعمل كأستاذ في DNB للتخصصات الفائقة في جراحة الأورام وجراحة الثدي في جامعة ماهاراشترا للعلوم الصحية. إيمانه هو "إضافة الحياة إلى سنوات" وتحسين نوعية الحياة ، وليس فقط إضافة سنوات إلى الحياة.

Prof. M.D. Yusuf Serdar Sakin was born in Nevşehir in 1978. After completing his primary and secondary education in Ankara, he graduated from the Faculty of Medicine at Gülhane Military Medical Academy in 2002.
Following his graduation, he served in Gole/Ardahan for two years. He started his internal medicine training at the Department of Internal Medicine, Gülhane Faculty of Medicine.
After completing his training, he worked as an internal medicine specialist in Ankara. A year later, he began additional training in the Department of Gastroenterology at Gülhane Faculty of Medicine and completed his training in 2014.
After graduation, Yusuf Serdar Sakin continued to work in the same department. He also received advanced endoscopy and Motility training at AMC Center in the Netherlands in 2017.
After obtaining the title of Associate Professor in 2017, he became a Professor in 2023.
He currently provides medical services to patients at Koru Ankara Hospital. His areas of medical interest include:

-Endoscopic retrograde cholangiopancreatography (ERCP)
-Push enteroscopy
-Endoscopic mucosal resection
-High-resolution manometry
-pH/pH-impedance metry analysis
-Advanced endoscopic procedures (stenting, dilation, etc.)
-Gastrointestinal motility disorders
-Gastroesophageal reflux disease
-Inflammatory bowel diseases
-Advanced endoscopic procedures and pancreatitis.

Prof. Dr. Erdem Akbal was born in 1978 in Kırıkkale. In 2015, he received training at the Johns Hopkins Hospital Advanced Endoscopy Unit, focusing on Endoscopic Ultrasonography and advanced endoscopic procedures. In 2017, he trained at the Amsterdam Academic Medical Center in techniques such as endoscopic submucosal dissection, endoscopic mucosal resection, diffuse esophageal spasm, and endoscopic full-thickness resection for treating early-stage gastrointestinal system tumors. He also received training in high-resolution manometry and POEM (Peroral Endoscopic Myotomy) for diagnosing esophageal diseases like achalasia. In 2018, he furthered his education in ESD and Balloon Enteroscopy at Jichi University.

Gastroenterologist

Crohn's disease

Ulcerative colitis

Other autoimmune diseases

Gastritis

Ulcers of the stomach and duodenum

Precancerous conditions of the gastrointestinal tract

Irritable bowel syndrome

Chronic diarrhea

Chronic constipation, etc.

SPECIALIZATION:

Gastroenterologist

EDUCATION:

Azerbaijan State Medical University

COURSES:

Graduated from the Azerbaijan State Medical University. In different years, he participated in seminars held in Azerbaijan by German, Colombian, Swiss, Russian and Ukrainian specialists on "Basics of Homotoxicology", gastroenterology, isopathy, acupuncture and neurotherapy, and received the relevant certificates. At the Sisli Etfal Hospital Egitim Araştırma in Istanbul he attended the refresher courses on "Metabolic Disorders and Obesity", Ege University of Izmir on "Inflammatory Bowel Diseases" and at the same time he attended the Congress on Bioregulatory Drugs in Germany. He attended the courses held Individual Medical Association in Ankara, on the topic of "PRP-CGF and Serum Ozonation". Currently working as a gastroenterologist in the clinic of biological medicine. Has successful results in the treatment of a number of chronic diseases of the gastrointestinal tract.

EXPERIENCE:

21 years old

Viral hepatitis A, B, C, D

Cirrhosis

Autoimmune liver diseases

Fatty liver

Diseases of the stomach and intestines

Diseases of the pancreas

Services in the field of biological medicine:

Treatment of various drug-induced liver poisonings, viral hepatitis (hepatitis B, hepatitis C), hepatosis, hepatosterosis, autoimmune hepatitis.

EDUCATION: Azerbaijan Medical University

EXPERIENCE:

2009-2010 General practitioner in a private clinic.

Clinic of biological medicine since 2011.

TRAINING AND MEMBERSHIP:

In 2013-2014, internship on viral hepatitis at the Department of Microbiology and Infection, as well as at the Department of Gastroenterology, Faculty of Medicine, Ege University, Turkey.

Ankara Hacettepe Hospital

الدكتور محمد منير العلو هو طبيب أمراض الجهاز الهضمي يتمتع بخبرة تزيد عن 12 عامًا ، متخصص في علاج أمراض القنوات الصفراوية والبنكرياس ، والكشف المبكر عن سرطان القولون ، والتخثر الداخلي ، وعلاج السمنة عن طريق بالون المعدة. حاصل على بكالوريوس الطب والجراحة ، بكالوريوس الطب والجراحة وما بعد التخرج من سوريا وباريس ، وهو ضليع في اللغة العربية والفرنسية والإنجليزية. لديه منشورات ومقالات وعروض تقديمية دولية مكثفة ، بالإضافة إلى برامج بحثية مختلفة تتعلق بتقليل مضاعفات ما بعد ERCP ومرض الاضطرابات الهضمية وسرطان القولون.